22649-28-1

Usage

Uses

Used in Pharmaceutical Industry:
2H-Chromene-3-carboxylic acid is utilized as a therapeutic agent for its anti-inflammatory and antioxidant properties, which can contribute to the treatment of various inflammatory and oxidative stress-related conditions.
Used in Antitumor Applications:
In the field of oncology, 2H-Chromene-3-carboxylic acid is employed as a potential antitumor agent, indicating its capacity to target and mitigate the growth of cancer cells, thereby offering a novel approach to cancer treatment.
Used in Antiviral Applications:
2H-CHROMENE-3-CARBOXYLIC ACID also serves as a potential antiviral agent, suggesting its ability to inhibit viral replication and infection, which could be beneficial in the development of treatments for viral diseases.
Used in Medicinal Chemistry and Drug Discovery:
2H-Chromene-3-carboxylic acid is used as a key building block in the synthesis of other organic compounds, playing a crucial role in the advancement of medicinal chemistry and the discovery of new drugs with diverse therapeutic applications.

InChI:InChI=1/C10H8O3/c11-10(12)8-5-7-3-1-2-4-9(7)13-6-8/h1-5H,6H2,(H,11,12)/p-1

Upstream product

• 215123-92-5 ethyl?6-iodo-2-(trifluoromethyl)-2H-chromene-3-carboxylate 
• 51593-69-2 2H-chromene-3-carbaldehyde 

Downstream Products

• 36044-49-2 methyl 2H-1-benzopyran-3-carboxylate 
• 41873-72-7 chlorure d'acide chromene carboxylique-3 
• 115822-61-2 (2H-chromen-3-yl)methanol 
• 115822-57-6 3,4-dihydro-2H-1-benzopyran-3-carboxylic acid 
• 19090-04-1 chroman-3-one 
• 1154742-93-4 (R)-N-(1-(2-fluoro-5-methyl-4-(methylsulfonamido)phenyl)ethyl)-2H-chromene-3-carboxamide 
• 1220889-14-4 C₂₁H₂₁FN₂O₂ 
• 1258077-58-5 C₂₅H₁₉FN₄O₂S 
• 60575-19-1 3,4-dihydro-3-amino-2H-benzopyran 

Relevant academic research and scientific papers

Systematic methodology for the development of biocatalytic hydrogen-borrowing cascades: Application to the synthesis of chiral α-substituted carboxylic acids from α-substituted α,β-unsaturated aldehydes

Ene-reductases (ERs) are flavin dependent enzymes that catalyze the asymmetric reduction of activated carbon-carbon double bonds. In particular, α,β-unsaturated carbonyl compounds (e.g. enals and enones) as well as nitroalkenes are rapidly reduced. Conversely, α,β-unsaturated esters are poorly accepted substrates whereas free carboxylic acids are not converted at all. The only exceptions are α,β-unsaturated diacids, diesters as well as esters bearing an electron-withdrawing group in α- or β-position. Here, we present an alternative approach that has a general applicability for directly obtaining diverse chiral α-substituted carboxylic acids. This approach combines two enzyme classes, namely ERs and aldehyde dehydrogenases (Ald-DHs), in a concurrent reductive-oxidative biocatalytic cascade. This strategy has several advantages as the starting material is an α-substituted α,β-unsaturated aldehyde, a class of compounds extremely reactive for the reduction of the alkene moiety. Furthermore no external hydride source from a sacrificial substrate (e.g. glucose, formate) is required since the hydride for the first reductive step is liberated in the second oxidative step. Such a process is defined as a hydrogen-borrowing cascade. This methodology has wide applicability as it was successfully applied to the synthesis of chiral substituted hydrocinnamic acids, aliphatic acids, heterocycles and even acetylated amino acids with elevated yield, chemo- and stereo-selectivity. A systematic methodology for optimizing the hydrogen-borrowing two-enzyme synthesis of α-chiral substituted carboxylic acids was developed. This systematic methodology has general applicability for the development of diverse hydrogen-borrowing processes that possess the highest atom efficiency and the lowest environmental impact. This journal is

Substituted benzopyran analogs for the treatment of inflammation

A class of benzopyrans, benzothiopyrans, dihydroquinolines, dihydronaphthalenes, and analogs thereof, is described for use in treating cyclooxygenase-2 mediated disorders. Compounds of particular interest are defined by Formula I'wherein X, A1, A2, A3, A4, R, R'', R1 and R2 are as described in the specification.